WayPath

WayPathWayPathWayPath
  • Home
  • About Us
  • Contact Us
  • More
    • Home
    • About Us
    • Contact Us

WayPath

WayPathWayPathWayPath
  • Home
  • About Us
  • Contact Us
#

Research- PP1

New class of metabolically active molecules

#

Experience

Over 50 years of combined scientific experience

#

Results

Help in eradicating cancer in our pets

About Us

Ground-breaking anti-cancer drug for companion animals

WayPath is a development-stage companion animal pharmaceutical company formed in 2019 and led by two Louisiana State University (“LSU”) oncology researchers with over 50 years of combined experience.

Patented

WayPath has developed new and innovative anti-cancer metabolic compounds for companion animals and holds the exclusive license and commercialization rights from LSU for over 300 variants of our lead compound, PP1 

Combating Cancer

6M new cancer diagnoses for canines each year
1 in 4 canines will be diagnosed with cancer 

Founder

Dr. Krzysztof Reiss

  • Director, Neurological Cancer Research, Stanley S. Scott Cancer Center School of Medicine, Hematology and Oncology, LSU Health Sciences Center
  • Over 25 years of experience in molecular and cell biology, which involves extensive basic research, mentoring, and
  • Over 165 publications

LinkedIn
Co-Founder

Dr. Branko Jursic

  • Professor of Medical Chemistry, Dept of Chemistry at University of New Orleans
  • Over 25 years as a synthetic medicinal chemist with a focus on natural product synthesis, heterocycles and carbohydrate chemistry with strong application of computational methodology that spans several decades

Find out more

Research

Download PDF
  • Privacy Policy
  • Terms and Conditions

WayPath

Copyright © 2024 WayPath - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept